Phase 1Completed
Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
A Phase 1 Study Assessing the Effect of Carbamazepine, a P-Glycoprotein Inducer, on the Pharmacokinetics of AT-527 in Healthy Adult Subjects
- Sponsor
- Atea Pharmaceuticals, Inc. (Industry)
- Enrollment
- 20 enrolled
- Conditions
- Healthy Volunteer Study
- Interventions
- Period 1: AT-527 550 mg; Period 2: carbamazepine; Period 3: AT-527 550 mg + carbamazepine; Period 3: AT-527 1100 mg + carbamazepine
- Ages
- adults, older adults
- Registry
- NCT04784000
Full record on ClinicalTrials.gov
From the registry
This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.
Primary outcomes
- Pharmacokinetics (PK) of AT-527 (RO7496998)
History
Last registry update
Primary completion
Registered
Started